Peptide Vial Shelf Life: Why the 28-Day Rule Is Not Universal

The claim that a peptide automatically degrades 28 days after reconstitution is repeated so often that it sounds like a scientific rule. It is not. Without data for the exact molecule, formulation, concentration, diluent, container and storage conditions, 28 days is an assumption — not a measured degradation point.

Where the 28-day number actually appears

Twenty-eight-day in-use periods appear prominently in insulin guidance and official insulin product labelling. For example, the U.S. prescribing information for Humalog permits an opened vial to be kept refrigerated or at room temperature below its stated limit for up to 28 days. That instruction belongs to that named insulin product and presentation; it is not a universal peptide rule.

SEROSTIM shows why blanket rules fail

Official SEROSTIM labelling gives different storage instructions for different presentations of the same active substance. A 4 mg vial reconstituted with the supplied bacteriostatic water may be refrigerated at 2–8°C for up to 14 days. The 5 mg and 6 mg presentations, reconstituted with sterile water, are labelled for immediate use with any unused portion discarded.

That is a useful real-world counterexample: even with the same active ingredient, the vial strength, diluent and presentation change the supported in-use period. There is no scientific basis for replacing those product-specific instructions with a universal 28-day clock.

Stability is not one variable

Peptide stability depends on interacting factors. Different sequences and formulations can respond very differently to the same storage conditions.

• Molecule and sequence: susceptibility to oxidation, deamidation, hydrolysis or aggregation varies.
• Formulation and pH: buffers, excipients and acidity can change degradation pathways.
• Diluent and concentration: sterile water and preserved diluents do not create identical systems.
• Container and handling: light, oxygen, agitation, adsorption, stopper integrity and repeated puncture can matter.
• Temperature history: the actual cold chain, excursions and freeze-thaw events matter more than a generic storage slogan.

Potency and microbiological quality are separate clocks

A chemical assay can show that the main compound remains present at high relative purity. It cannot establish that a repeatedly accessed vial is sterile or that bacterial endotoxins are absent. Conversely, a microbiological limit does not prove that the peptide chemically degrades on that date.

This distinction is why an HPLC result taken weeks or months after reconstitution can be informative without creating a universal use-by period. Independent analytical examples shared online have shown that some reconstituted compounds can retain high measured purity beyond 28 days under particular conditions. Those observations are compound- and formulation-specific, and purity testing alone does not establish sterility.

What credible evidence looks like

1. Identify the exact molecule, formulation, concentration, diluent and container.
2. Define the storage and handling conditions actually studied.
3. Measure identity, potency, purity and relevant degradation products over time.
4. Assess sterility and bacterial endotoxins separately when those attributes are claimed.
5. State a supported period only for the tested product and conditions.

FDA stability guidance follows the same underlying principle: expiration periods should be supported by stability studies designed around the product's storage conditions and stability characteristics. A date repeated by an influencer is not a substitute for that evidence.

Bottom line

Do not confuse a product-specific in-use period, a sterility policy, an HPLC snapshot and a general degradation claim. They answer different questions. This article is an evidence reference, not medical advice.